However, only 2.8% of patients with ESCC with EGFR amplification achieved a response in a phase II trial of the EGFR inhibitor gefitinib, and the EGFR expression level was positively associated with a better prognosis [32]. The gene discussed is EGFR; the disease is esophageal squamous cell carcinoma.